| Bioactivity | ZLM-66 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTIs) with an IC50 of 41 nM for wild-type (WT) HIV-1 reverse transcriptase and an EC50 value of 13 nM for wild-type HIV-1. ZLM-66 is a Doravirine (HY-16767) analogs. ZLM-66 can be used for the research of AIDS[1]. |
| Invitro | ZLM-66 (0.0016-125 µg/ml, 5 d) inhibits HIV-1 and HIV-1 mutant strains in MT-4 cells[1]. Cell Viability Assay[1] Cell Line: |
| In Vivo | Zlm-66 (1-5 mg/kg; i.v. and p.o. once) shows good druggability and have a good effect in vivo after oral administration[1].1.19Pharmacokinetic Parameters of ZLM-66 in rat[1]. |
| Name | ZLM-66 |
| Formula | C24H18F3N5O3 |
| Molar Mass | 481.43 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhao LM, et al. Discovery of novel biphenyl-substituted pyridone derivatives as potent non-nucleoside reverse transcriptase inhibitors with promising oral bioavailability. Eur J Med Chem. 2022 Jun 30;240:114581. |